Bridgette Roberts, M.D. is the Chief Executive Officer of AI Therapeutics. Dr. Roberts joins AI Therapeutics after four years as an entrepreneur in residence at Fortress Biotech, where she was positioned to spin out as a CEO of a target biotechnology asset-holding subsidiary. Prior to this, she spent fifteen years in healthcare investing as a portfolio manager at hedge funds including Third Point, CDP Capital, DKR Capital and her own hedge fund, YYC Capital, which landed her on Fortune's 40 under 40 Ones to Watch list. Over her investment career, she conducted activist work in several biotechnology companies, including Ligand Pharmaceuticals where she served as a Board Member. Dr. Roberts has an M.D. degree from NYU and a BA degree in Physics and Chemistry from Harvard.